Also known as: UCB
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. The company focuses on research and development of medicines for severe diseases, especially in CNS disorders, inflammatory diseases, and oncology.
China's pharma industry hit record clinical drug trials and out-licensing deal values in 2025 and H1 2026, with NMPA approvals surging. The growth has drawn US Senate scrutiny and new bipartisan oversight legislation.
The European Commission has approved KYGEVVI (doxecitine and doxribtimine) as the first treatment for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial disease. Clinical studies showed the drug reduces death risk by 95% and helps 84% of patients regain motor functions. The approval covers pediatric and adult patients with symptom onset before age 12.
AbbVie reported Q4 earnings that beat consensus estimates with $16.62 billion in revenue, while facing competitive setbacks in psoriatic arthritis and Medicare pricing challenges for Botox.
Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.
